#1 Clinical Trials Search in Europe

Study on Treprostinil Palmitil Inhalation Powder for Patients with Pulmonary Hypertension and Interstitial Lung Disease

4 1

What is this study about?

This clinical trial is focused on studying the effects of a treatment for Pulmonary Hypertension associated with Interstitial Lung Disease. The treatment being tested is called Treprostinil Palmitil Inhalation Powder, also known by its code name INS1009. This medication is administered as an inhalation powder, which means it is breathed in through a device designed for this purpose. The study also involves a placebo, which is a substance with no active medication, to compare the effects of the treatment.

The purpose of the study is to evaluate the safety and tolerability of long-term use of Treprostinil Palmitil Inhalation Powder in participants with Pulmonary Hypertension associated with Interstitial Lung Disease. Participants who have completed previous related studies are eligible to join this extension study. The study will monitor participants over a period of time to observe any side effects and to assess how well the treatment is tolerated. Participants will be asked to use the inhalation powder regularly and attend follow-up visits to track their progress.

Throughout the study, various health measurements will be taken to assess the effectiveness of the treatment. These include tests to measure lung function and exercise capacity, as well as blood tests to check for specific markers related to the disease. The study aims to provide valuable information on the long-term use of Treprostinil Palmitil Inhalation Powder, which could help improve treatment options for people with Pulmonary Hypertension associated with Interstitial Lung Disease.

1 joining the study

Participation begins after completing a previous study related to pulmonary hypertension with interstitial lung disease. Eligibility is confirmed through baseline screening assessments if more than 30 days have passed since the last study visit.

2 medication administration

The medication used is treprostinil palmitil inhalation powder. It is administered through inhalation. Dosage strengths include 80 micrograms, 160 micrograms, or 320 micrograms, depending on the specific requirements of the study.

3 monitoring and assessments

Regular assessments are conducted to monitor safety and effectiveness. These include measuring the distance walked in six minutes (6MWD), lung function tests such as FVC and FEV1, and blood tests for NT-proBNP concentration.

Assessments occur at specific intervals: Month 6, Month 12, Month 18, and Month 24. Additional evaluations include questionnaires to assess quality of life and any changes in health status.

4 tracking clinical events

The study tracks the frequency and severity of any adverse events. Clinical worsening events, such as hospitalization or the need for additional therapy, are also monitored.

5 study duration

The study is expected to continue until April 15, 2026. Participation involves regular follow-ups and adherence to the study protocol throughout this period.

Who Can Join the Study?

  • Participants must have completed the end of treatment visit in Study INS1009-211 or any other related study for Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD). This means they have finished a previous study related to their lung condition.
  • If the new study was not available when they finished the previous study, they can still join within one year of completing the previous study.
  • If more than 30 days have passed since the end of their previous study, participants need to complete some initial checks to confirm they can join the new study. These checks are called baseline screening assessments.
  • Participants must be able to understand and sign a document called informed consent. This document explains what they need to do and any rules they need to follow during the study.
  • Both male and female participants are eligible to join the study.

Who Cannot Join the Study?

  • Patients who have not participated in Study INS1009-211 or other related studies involving TPIP for Pulmonary Hypertension Associated with Interstitial Lung Disease. This condition involves high blood pressure in the lungs due to lung disease.
  • Patients who are not within the specified age range for the study.
  • Patients who are not part of the specified clinical trial groups.
  • Patients who are not male or female, as both genders are included in the study.
  • Patients who are considered part of a vulnerable population, which means they might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Technische Universitaet Dresden Dresden Germany
Bellvitge University Hospital L'hospitalet De Llobregat Spain
DRK Kliniken Berlin Berlin Germany
Azienda Ospedaliera Universitaria Federico II Di Napoli Naples Italy

Other Sites

Site Name City Country Status
Centre hospitalier universitaire de Liege Liege Belgium
Ruhrlandklinik Westdeutsches Lungenzentrum Am Universitaetsklinikum Essen gGmbH Essen Germany
Fondazione IRCCS San Gerardo Dei Tintori Monza Italy
Evangelische Lungenklinik Berlin Krankenhausbetriebs gGmbH Berlin Germany
Multimedica S.p.A. Milan Italy
Universidade De Santiago De Compostela Santiago De Compostela Spain
Justus-Liebig-Universitaet Giessen Giessen Germany
Thoraxklinik Heidelberg gGmbH Heidelberg Germany
Istituto Mediterraneo Per I Trapianti E Terapie Ad Alta Specializzazione S.r.l. Palermo Italy
Servei De Salut De Les Illes Balears Palma Spain
Kpegimhh dbt Uksgdjlwldyz Mfdgpgop Aub Munich Germany
Hfyzbyme Vhpo dmsohkbk Barcelona Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not recruiting
11.05.2023
Germany Germany
Not recruiting
11.05.2023
Italy Italy
Not recruiting
11.05.2023
Spain Spain
Not recruiting
11.05.2023

Trial locations

Investigated drugs:

Treprostinil Palmitil Inhalation Powder (TPIP) is a medication being studied for its long-term safety and effectiveness in treating pulmonary hypertension associated with interstitial lung disease. It is administered as an inhalation powder, which means it is breathed in through the mouth using a special device. This medication is designed to help improve blood flow in the lungs, which can reduce the symptoms of pulmonary hypertension and improve the patient’s ability to exercise and perform daily activities.

Pulmonary Hypertension Associated with Interstitial Lung Disease – This condition involves high blood pressure in the blood vessels of the lungs, occurring alongside interstitial lung disease, which affects the tissue and space around the air sacs of the lungs. The disease progresses as the blood vessels in the lungs become narrowed, blocked, or destroyed, leading to increased pressure and strain on the heart. Over time, this can cause the heart to weaken and struggle to pump blood effectively. Symptoms may include shortness of breath, fatigue, dizziness, and swelling in the legs and ankles. As the condition advances, these symptoms can become more pronounced, affecting daily activities and quality of life.

Trial ID:
2023-505540-19-00
Protocol code:
INS1009-212
NCT ID:
NCT05649722
Trial Phase:
Therapeutic use (Phase IV)

Other Trials to Consider

  • Testing the safety of stopping riociguat in patients with chronic thromboembolic pulmonary hypertension after successful balloon pulmonary angioplasty treatment

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +4